Inhibition of PLK1 Destabilizes EGFR and Sensitizes EGFR-Mutated Lung Cancer Cells to Small Molecule Inhibitor Osimertinib

por Eggermont, Carolien, Gutierrez, Gustavo J., De Grève, Jacques, Giron, Philippe
Publicado 2023

Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer

por Noeparast, Amir, Giron, Philippe, De Brakeleer, Sylvia, Eggermont, Carolien, De Ridder, Ulrike, Teugels, Erik, De Grève, Jacques
Publicado 2018

The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer

por Eggermont, Carolien, Giron, Philippe, Noeparast, Maxim, Vandenplas, Hugo, Aza-Blanc, Pedro, Gutierrez, Gustavo J., De Grève, Jacques
Publicado 2022

Targeting USP13‐mediated drug tolerance increases the efficacy of EGFR inhibition of mutant EGFR in non‐small cell lung cancer

por Giron, Philippe, Eggermont, Carolien, Noeparast, Amir, Vandenplas, Hugo, Teugels, Erik, Forsyth, Ramses, De Wever, Olivier, Aza‐Blanc, Pedro, Gutierrez, Gustavo J., De Grève, Jacques
Publicado 2021

CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition

por Noeparast, Amir, Giron, Philippe, Noor, Alfiah, Bahadur Shahi, Rajendra, De Brakeleer, Sylvia, Eggermont, Carolien, Vandenplas, Hugo, Boeckx, Bram, Lambrechts, Diether, De Grève, Jacques, Teugels, Erik
Publicado 2019